Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.46 |
| ▸ | ACE | P12821 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PEPD | P12955 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17352470 | 1.00 | OPRM1 (0.46) | OPRM1ACEKDM4EF2REN | |
| SCHEMBL17352458 | 0.96 | OPRM1 (0.43) | OPRM1ACEKDM4EF2REN | |
| SCHEMBL29355564 | 0.95 | GRB2 (0.47) | OPRM1ACEKDM4EF2REN | |
| SCHEMBL29776753 | 0.93 | OPRM1 (0.48) | OPRM1ACEKDM4EF2REN | |
| SCHEMBL29886469 | 0.93 | OPRM1 (0.46) | OPRM1ACEKDM4EF2REN | |
| SCHEMBL17352471 | 0.92 | OPRM1 (0.39) | OPRM1ACEKDM4EF2REN | |
| SCHEMBL29374739 | 0.92 | OPRM1 (0.45) | OPRM1F2 | |
| SCHEMBL31065472 | 0.92 | OPRM1 (0.45) | OPRM1F2 | |
| SCHEMBL29377214 | 0.91 | DPP4 (0.50) | OPRM1ACEKDM4EF2REN | |
| SCHEMBL29363345 | 0.91 | OPRM1 (0.46) | OPRM1F2XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110964115-B | Production of heterodimeric proteins | 健玛保 | 2024-03-12 | — | — | CN | claimed |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | UNIV LELAND STANFORD JUNIOR (US) | 2026-02-19 | — | — | US | disclosed |
| CN-113811545-B | Antibodies specific for BTN2 and uses thereof | 感应检查疗法公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-113767115-B | Therapeutic interferon alpha 1 proteins | 奥里尼斯生物科学股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119855605-A | Antibodies to CLDN4 and methods of use thereof | 丹娜-法伯癌症研究院 | 2025-04-18 | — | — | CN | disclosed |
| CN-114127114-B | Cancer-associated antibody compositions and methods of use | ABSCI公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119331096-A | Human antibodies against tissue factor | 健玛保 | 2025-01-21 | — | — | CN | disclosed |
| CN-119285787-A | Bispecific anti-CD 37 antibodies, monoclonal anti-CD 37 antibodies, and methods of use thereof | 健玛保控股有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-118994414-A | Chimeric proteins based on TIGIT and LIGHT | 沙塔克实验室有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118754990-A | Fibroblast binding agent and use thereof | 奥里尼斯生物科学公司股份有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-106632678-B | Human antibodies to tissue factor | 健玛保 | 2022-05-31 | — | — | CN | disclosed |
| CN-114514246-A | Antibodies specific for NECTN-4 and uses thereof | 埃克斯-马赛大学 | 2022-05-17 | — | — | CN | disclosed |
| CN-114478792-A | Bispecific antibodies against CD3 and CD20 | 根马布股份公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114450304-A | Anti-mullerian tube inhibitor antibody and use thereof | 国家医疗保健研究所 | 2022-05-06 | — | — | CN | disclosed |
| CN-109069573-B | Single domain antibodies that bind CD20 | 弗拉芒区生物技术研究所 | 2022-04-05 | — | — | CN | disclosed |
| CN-114258401-A | Antibodies specific for CD38 and uses thereof | INSERM(法国国家健康医学研究院) | 2022-03-29 | — | — | CN | disclosed |
| CN-107253992-B | Monoclonal antibody against HER2 | 根马布股份公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-114127114-A | Cancer-associated antibody compositions and methods of use | 目标发现联合第二附属有限责任公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-107660214-B | Bispecific antibodies against CD3 and CD20 | 根马布股份公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-113993541-A | Alkaline phosphatase-based oncology therapy | 合成生物制品有限公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | ADAR, ZFR, SLIRP | OPRM1 1894/4885ACE 4661/4885KDM4E 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.